Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma - Concepedia

Concepedia

Publication | Closed Access

Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma

1.3K

Citations

69

References

2019

Year

Timothy F. Cloughesy, Aaron Mochizuki, Joey Orpilla, Willy Hugo, Tom B. Davidson, Anthony Wang, Benjamin M. Ellingson, Julie Rytlewski, Catherine Sanders, Eric S. Kawaguchi,

Nature Medicine

Neuro-oncologyNeoadjuvant Anti-pd-1 ImmunotherapyTumor ImmunologyCancer ImmunosurveillanceGliomaMedicineImmunologyTumor ImmunityTherapeutic VaccineImmune Checkpoint InhibitorHigh-grade GliomasCancer TreatmentRecurrent GlioblastomaImmunotherapyOncologyRadiation OncologySystemic Immune Responses

References

	Year	Citations

Page 1

Page 1